SCHEMBL25335754

SCHEMBL25335754

Nc1cc(Nc2nccc(-c3cccc(C(=O)O)c3)n2)ccc1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.61
ABL1 P00519 3/20 0.61
BCR P11274 2/20 0.61
PRKCA P17252 2/20 0.61
MAPK8 P45983 3/20 0.55
PIK3CG P48736 2/20 0.55
GSK3B P49841 2/20 0.55
CAMKK2 Q96RR4 2/20 0.55
CAMK2D Q13557 4/20 0.54
AURKA O14965 1/20 0.53
MAPK10 P53779 1/20 0.51
PLK1 P53350 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
PRKD3 O94806 1/20 0.49
PRKCG P05129 1/20 0.49
PRKCB P05771 1/20 0.49
PDGFRB P09619 1/20 0.49
SRC P12931 1/20 0.49
PDGFRA P16234 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31119111 1.00 SYK (0.61) SYKABL1BCRPRKCAMAPK8
SCHEMBL25980185 0.84 PLK1 (0.65) ABL1BCRPRKCAGSK3BCAMK2D
SCHEMBL30554522 0.84 PLK1 (0.65) ABL1BCRPRKCAGSK3BCAMK2D
SCHEMBL31119054 0.82 SYK (0.50) SYKABL1BCRMAPK8GSK3B
SCHEMBL25337669 0.82 SYK (0.50) SYKABL1BCRMAPK8GSK3B
SCHEMBL25337094 0.81 ABL1 (0.75) SYKABL1BCRPRKCAMAPK8
SCHEMBL31118910 0.81 ABL1 (0.75) SYKABL1BCRPRKCAMAPK8
SCHEMBL5379812 0.80 ABL1 (0.77) SYKABL1BCRPRKCAMAPK8
SCHEMBL27115954 0.78 ABL1 (0.74) SYKABL1BCRPRKCAMAPK8
SCHEMBL25337710 0.77 PLK1 (0.74) ABL1BCRPRKCAMAPK8PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2025-07-29 US disclosed
US-12168646-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2024-12-17 US disclosed
EP-4472953-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF Nexys Therapeutics, Inc. (US) 2024-12-11 EP disclosed
US-20240279185-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-08-22 US disclosed
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-06-27 US disclosed
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2024-06-27 US disclosed
WO-2023150197-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed
WO-2023150197-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 SYK 3388/4885ABL1 3084/4885BCR 1887/4885
US-20240279185-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 SYK 3388/4885ABL1 3084/4885BCR 1887/4885
US-12168646-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 SYK 3388/4885ABL1 3084/4885BCR 1887/4885
US-20240208913-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, ARNT, NR1H2 SYK 3388/4885ABL1 3084/4885BCR 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.